Table 1.
The characteristics of all the cases recruited in the study (n = 84).
| Sex (male) | 51 (60.7%) |
| Age (years) | 58 [22,88] |
| Follow-up duration (months) | 36 [1,126] |
| Medium tumor diameter (cm) | 5 [1.1,14.5] |
| Smoking status | 21 (25.0%) |
| Surgery | 76 (90.5%) |
| Chemotherapy | 32 (38.1%) |
| Radiotherapy | 9 (10.7%) |
| WHO histological classification | |
| Low-risk thymomas (A/AB/B1) | 34 (40.5%) |
| High-risk thymomas (B2/B3) | 22 (26.2%) |
| Thymic carcinomas (TCs) | 28 (33.3%) |
| Masaoka–Koga stage | |
| I | 23 (27.4%) |
| II | 24 (28.6%) |
| III | 15 (17.8%) |
| IV | 22 (26.2%) |
| 8th UICC/AJCC TNM staging | |
| I | 43 (51.2%) |
| II | 4 (2.8%) |
| III | 15 (17.8%) |
| IV | 22 (26.2%) |
| Clinical symptoms | |
| Asymptomatic | 31 (36.9%) |
| Respiratory symptoms | 11 (13.1%) |
| Chest pain/chest distress | 21 (25.0%) |
| Myasthenia gravis | 12 (14.3%) |
| Other symptoms | 9 (10.7%) |
Respiratory symptoms: cough, pneumonia.
Other symptoms: lumbago, trauma, gout, dizziness, lymphedema.